(Reuters) - BOSTON, July 26 - Celgene Corp. , the top maker of drugs to treat multiple myeloma, said on Thursday its second-quarter earnings rose on soaring sales of its newest product, Revlimid.
Net profit rose to $54.9 million, or 13 cents a share, from $9.6 million, or 3 cents a share, a year earlier.
Read more at Reuters.com Market News
Net profit rose to $54.9 million, or 13 cents a share, from $9.6 million, or 3 cents a share, a year earlier.
Read more at Reuters.com Market News
No comments:
Post a Comment